Start free trial

Latest NRG Therapeutics News & Updates

See the latest news and media coverage for NRG Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
NRG Therapeutics

Clinical-stage neuroscience company developing mitochondrial-targeted therapies for neurodegenerative diseases

nrgtherapeutics.com
Headquarters
Stevenage, United Kingdom
Company type
Private company
Number of employees
24–50
Industry
Pharmaceuticals

Last updated

Latest news about NRG Therapeutics

In short: NRG Therapeutics advanced NRG5051 into first-in-human Phase 1 trials and a PET biodistribution study for ALS and Parkinson's.

Company announcements

NRG Therapeutics

NRG Therapeutics doses first participants in NRG5051 Phase 1 trial

The randomized double-blind study assesses safety, tolerability, and pharmacokinetics in healthy volunteers at CHDR in Leiden. It targets ALS/MND and Parkinson’s.

Unlock all announcements with a

Media coverage

The Manila Times

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS ...

STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. ("NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial...

Unlock all articles with a

Never miss news about NRG Therapeutics

Track NRG Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NRG Therapeutics competitors & trending companies

Browse news for competitors to NRG Therapeutics and other trending companies.